AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 38.4% according to JP Morgan.
AZN.L
JP Morgan set a target price of 14,000 GBX for the company, which when compared to the AstraZeneca plc share price of 10,114 GBX at opening today (15/11/2024) indicates a potential upside of 38.4%. Trading has ranged between 9,461 (52 week low) and 13,388 (52 week high) with an average of 2,372,380 shares exchanging hands daily. The market capitalisation at the time of writing is £156,025,898,582.
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.
AstraZeneca plc 38.4% potential upside indicated by JP Morgan
- Written by: Charlotte Edwards
Latest Company News
AstraZeneca has started trading its ordinary shares on the NYSE for the first time, aligning its listings across New York, London and Stockholm under a harmonised structure.
Under a new agreement with CSPC Pharmaceuticals, AstraZeneca will advance eight programmes targeting obesity and weight-related conditions, initially progressing four assets through Phase I.
AstraZeneca PLC has notified of the voluntary withdrawal of its American Depositary Shares and certain debt securities from The Nasdaq Stock Market LLC.
AstraZeneca and Daiichi Sankyo have received US FDA approval for Enhertu in combination with pertuzumab as a 1st-line treatment for adults with unresectable or metastatic HER2-positive breast cancer.
AstraZeneca has received US approval for Imfinzi combined with FLOT chemotherapy for adults with resectable early-stage and locally advanced gastric and gastroesophageal junction cancers.
AstraZeneca has confirmed a $2 billion investment to expand its manufacturing presence in Maryland, including a larger biologics facility in Frederick and a new clinical manufacturing site in Gaithersburg.
